HHS announces savings for 27 Medicare Part B drugs

15 March 2023
centers-for-medicare-and-medicaid-services-big

The US Department of Health and Human Services (HHS), through the Centers for Medicare and Medicaid Services (CMS), has announced 27 prescription drugs for which Part B beneficiary coinsurances may be lower from April 1 to June 30.

These drugs include the inflammatory diseases med Humira (adalimumab), the CAR T-cell therapy Yescarta (axicabtagene ciloleucel) and the antibody-drug conjugate Padcev (enfortumab vedotin).

Under President Joe Biden’s Inflation Reduction Act (IRA), some people with Medicare who take these drugs may save between $2 and $390 per average dose starting April 1, depending on their individual coverage.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology